Acquiring Company
Chiesi Global Rare Diseases
Acquired Company
Amryt
Description
Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.
Quick answer
Chiesi Global Rare Diseases is acquiring Amryt, announced April 12, 2023.
- How much did Chiesi Global Rare Diseases pay for Amryt?
- The deal value was not disclosed.
- What does Chiesi Global Rare Diseases do?
- Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases.
Source: Fundz verified event record.
Other recent acquisitions in Non Profit and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Sobi To Acquire Cti Biopharma (May 10, 2023)
- Sumitovant Biopharma Completes Acquisition Of Myovant Sciences (March 10, 2023)
- Medtronic To Acquire Wearable Insulin Patch Maker Eoflow (May 25, 2023)
- Genesis Drug Discovery & Development (Gd3), A Member Of Genesis Global Group, Acquires Jss Medical Research To Expand Its Clinical Services Portfolio (May 10, 2023)
- Shockwave Medical Completes Acquisition Of Neovasc (April 11, 2023)
- Rhythm Pharmaceuticals Announces Acquisition Of Xinvento B.V. And Portfolio Of Investigational Therapeutics (February 27, 2023)
Who to call at Chiesi Global Rare Diseases, and when
When Chiesi Global Rare Diseases changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Chiesi Global Rare Diseases raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Chiesi Global Rare Diseases, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Chiesi Global Rare Diseases. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Chiesi Global Rare Diseases makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Amryt?
Amryt was acquired by Chiesi Global Rare Diseases. The deal was reported on April 12, 2023. Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. Chiesi Global Rare Diseases is privately held and operates in Biotechnology.
When did Chiesi Global Rare Diseases acquire Amryt?
Chiesi Global Rare Diseases's acquisition of Amryt was reported on April 12, 2023. Chiesi Farmaceutici S.p.A. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Amryt do?
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.